Comparative Pharmacology
Head-to-head clinical analysis: CYPROHEPTADINE HYDROCHLORIDE versus DISOBROM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYPROHEPTADINE HYDROCHLORIDE versus DISOBROM.
CYPROHEPTADINE HYDROCHLORIDE vs DISOBROM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cyproheptadine is a potent antihistamine (H1 receptor antagonist) and antiserotonergic agent (5-HT2 receptor antagonist). It also exhibits weak anticholinergic and sedative properties. It blocks histamine-mediated vasodilation, increased capillary permeability, and pruritus, as well as serotonin-mediated effects on appetite and mood.
DISOBROM is a synthetic compound that acts as a partial agonist at benzodiazepine sites on GABAA receptors, potentiating GABAergic neurotransmission. It also exhibits antagonistic activity at peripheral benzodiazepine receptors (TSPO).
4 mg orally three times daily; range 4-20 mg/day, not to exceed 0.5 mg/kg/day
DISOBROM is not a recognized drug. Please verify the name.
None Documented
None Documented
Terminal half-life approximately 8–16 hours in adults; may be prolonged in elderly or hepatic impairment.
Terminal elimination half-life is 8-12 hours in adults with normal renal function; prolonged to 20-30 hours in severe renal impairment (CrCl <30 mL/min).
Primarily renal (appreciable unchanged drug and metabolites); biliary/fecal elimination minor (<5%).
Primarily renal excretion of unchanged drug (60-70%) and glucuronide conjugate (20-30%); fecal excretion accounts for <10%.
Category A/B
Category C
Antihistamine
Antihistamine/Decongestant Combination